Neoadjuvant chemotherapy plus trastuzumab in stage II/III breast cancer with low HER2 expression

被引：1
|
作者：
Khan, Qamar J.
O'Dea, Anne
Fabian, Carol J.
Connor, Carol Sue
McGinness, Marilee
Mammen, Joshua Matthew Varghise
Wagner, Jamie Lynn
Baccaray, Stella
Springer, Michelle
Yeh, Henry
Sharma, Priyanka
机构：
[1] Univ Kansas Med Ctr, Kansas City, KS USA
[2] Drieling Schmidt Canc Inst, Hays, KS USA
[3] Univ Kansas Med Ctr, Westwood, KS USA
[4] Univ Kansas, Kansas City, KS USA
[5] Univ Kansas, Olathe, KS USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.1039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1039
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Correction to: Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2‑positive breast cancer?
    Silvia Antolín
    Lucía García-Caballero
    Cristina Reboredo
    Aurea Molina
    Joaquín Mosquera
    Ángel Vázquez-Boquete
    Rosalía Gallego
    Mari Paz Santiago
    Ángel Concha
    Eva Pérez
    Lourdes Calvo
    Tomás García-Caballero
    Virchows Archiv, 2021, 479 : 859 - 859
  • [22] Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer
    Gennari, Alessandra
    De Tursi, Michele
    Carella, Consiglia
    Ricevuto, Enrico
    Orlandini, Cinzia
    Frassoldati, Antonio
    Conte, Pierfranco
    Bruzzi, Paolo
    Iacobelli, Stefano
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (01) : 131 - 136
  • [23] HER2 expression-based approach of neoadjuvant chemotherapy with doxorubicin plus cyclophosphamide or docetaxel plus cyclophosphamide for operable breast cancer
    Ishikawa, Takashi
    Shimizu, Daisuke
    Takeshi, Sasaki
    Tanabe, Mikiko
    Ota, Ikuko
    Kito, Ayako
    Nozawa, Akinori
    Kawachi, Kae
    Morita, Satoshi
    Chishima, Takashi
    Ichikawa, Yasushi
    CANCER RESEARCH, 2009, 69
  • [24] Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer
    Alessandra Gennari
    Michele De Tursi
    Consiglia Carella
    Enrico Ricevuto
    Cinzia Orlandini
    Antonio Frassoldati
    Pierfranco Conte
    Paolo Bruzzi
    Stefano Iacobelli
    Breast Cancer Research and Treatment, 2009, 115 : 131 - 136
  • [25] Her2 Status Following Neoadjuvant Trastuzumab Therapy for Primary Breast Cancer
    Sanders, M. A. G.
    Richardson, A. L.
    Ly, A.
    LABORATORY INVESTIGATION, 2011, 91 : 62A - 62A
  • [26] Her2 Status Following Neoadjuvant Trastuzumab Therapy for Primary Breast Cancer
    Sanders, M. A. G.
    Richardson, A. L.
    Ly, A.
    MODERN PATHOLOGY, 2011, 24 : 62A - 62A
  • [27] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    Luciana de Moura Leite
    Marcelle Goldner Cesca
    Monique Celeste Tavares
    Debora Maciel Santana
    Erick Figueiredo Saldanha
    Paula Tavares Guimarães
    Daniella Dias Silva Sá
    Maria Fernanda Evangelista Simões
    Rafael Lima Viana
    Francisca Giselle Rocha
    Simone Klog Loose
    Sinara Figueiredo Silva
    Rafaela Pirolli
    Camilla Albina Zanco Fogassa
    Bruna Raphaeli Silva Mattos
    Fernando Augusto Batista Campos
    Solange Moraes Sanches
    Vladmir Cláudio Cordeiro de Lima
    Noam Falbel Pondé
    Breast Cancer Research and Treatment, 2021, 190 : 155 - 163
  • [28] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    de Moura Leite, Luciana
    Cesca, Marcelle Goldner
    Tavares, Monique Celeste
    Santana, Debora Maciel
    Saldanha, Erick Figueiredo
    Guimaraes, Paula Tavares
    Sa, Daniella Dias Silva
    Simoes, Maria Fernanda Evangelista
    Viana, Rafael Lima
    Rocha, Francisca Giselle
    Loose, Simone Klog
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla Albina Zanco
    Mattos, Bruna Raphaeli Silva
    Campos, Fernando Augusto Batista
    Sanches, Solange Moraes
    de Lima, Vladmir Claudio Cordeiro
    Ponde, Noam Falbel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (01) : 155 - 163
  • [29] Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in stage II-III HER2-positive breast cancer: The TRAIN-4 study
    Louis, F. M.
    van der Voort, A.
    Schroder, C. P.
    Scholten, A. N.
    Wesseling, J.
    Peeters, M-J. T. F. D. Vrancken
    Mann, R. M.
    Sonke, G. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S347 - S347
  • [30] Association of HER2 655 ile→Val polymorphism with pathological response to neoadjuvant chemotherapy and trastuzumab in breast cancer
    Astorga, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345